foray

SynopsisThe under-performing pharma company’s foray into a competitive services business like diagnostics may seem counter-intuitive, as Lupin has been facing many challenges in its US business, including pricing pressure, increased competitive intensity, compliance and drug settlement costs.AgenciesMoreover, it helps spread the risk across businesses, combat competition better and offer a holistic disease management from prevention…Continue Reading